Skip to main content
. 2018 Oct 26;19(11):3352. doi: 10.3390/ijms19113352

Figure 9.

Figure 9

Photomicrographs of the morphological changes observed in control, Selenite, Bevacizumab (BV), Selenobevacizumab (Se-BV), Trastuzumab (TZ) and Selenotrastuzumab-treated HME 50-5E Cells. Treatment of HME 50-5E cells with Selenite, Se-BV and Se-TZ did not induce severe morphological cell changes in comparison to those seen in the selenium-treated MDA-MB-468 cells. Representative fields of view of HME50-5E cells. Cells were photographed under phase contrast conditions at 20× magnification. Scale bar = 100 µm.